person · Reporting owner

Saoud Jay

Disclosed activity across 1 company

Tapewire entity: 145965
SEC CIK: 0001716202

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Minerva Neurosciences, Inc.NERV · Entity 6245	SVP and Head of R&D	October 13, 2020	October 14, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Minerva Neurosciences, Inc.

Report date October 13, 2020 · Filed October 14, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2030-10-12	Direct	100,000	Reported balance After 2020-10-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-13 · Grant · Acquired 100,000 · Balance 100,000 F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 13, 2020 Filed Oct 14, 2020 21:16 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (right to buy) · Derivative	100,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001209191-20-054800 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-12 F1 · derivative.exercise_date: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022. Read SEC document
June 19, 2020 Filed Aug 17, 2020 20:31 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (right to buy) · Derivative	236,202	$0.00 Strike: $7.11	$0.00	Disclosure SEC source: 0001209191-20-046954 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,202 Underlying: Common Stock · 236,202 shares Expires 2029-12-31 F1 · derivative.exercise_date: This option was granted by Issuer's Board of Directors on December 31, 2019 contingent upon stockholder approval of an amendment and restatement of Issuer's equity incentive plan to increase the number of shares available for issuance under such plan, which was received on June 19, 2020. This option vests 25% on December 31, 2020 and then in quarterly installments over 3 years thereafter. Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:52 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (right to buy) · Derivative	63,798	$0.00 Strike: $7.11	$0.00	Disclosure SEC source: 0001209191-20-001125 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,798 Underlying: Common Stock · 63,798 shares Expires 2029-12-30 F1 · derivative.exercise_date: This option vests 25% on December 31, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document
December 11, 2018 Filed Dec 13, 2018 21:44 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (right to buy) · Derivative	96,000	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0001209191-18-062465 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests 25% on December 11, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document
December 13, 2017 Filed Dec 15, 2017 21:39 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (Right to Buy) · Derivative	175,000	$0.00 Strike: $6.10	$0.00	Disclosure SEC source: 0001209191-17-065956 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: This option vests as to 25% of the shares on December 13, 2018 and then in quarterly installments over 3 years thereafter. Read SEC document
September 01, 2017 Filed Sep 5, 2017 20:37 UTC	Minerva Neurosciences, Inc. NERV · Entity 6245	GrantEmployee Stock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $6.45	$0.00	Disclosure SEC source: 0001209191-17-051332 · doc4.xml · derivative · entry 1 Saoud Jay · CIK 0001716202 · SVP and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2017-08-31 F1 · derivative.exercise_date: This option vested as to 25% of the shares on September 1, 2018 and then in quarterly installments over 3 years thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.